Results 251 to 260 of about 280,511 (396)

Resistance mechanisms and clonal dynamics in mantle cell lymphoma treated with sequential BTKi and venetoclax therapy

open access: yesThe Journal of Pathology, EarlyView.
Abstract In recent years, targeted therapies have become the standard of care for refractory/relapsed mantle cell lymphoma (MCL). Although the mutational profile of MCL has been extensively studied, there is a lack of understanding of resistance mechanisms and genetic factors that impact the response to novel treatments.
Tamás László   +19 more
wiley   +1 more source

Post-translational cleavage generates truncated IgY forms in the snake <i>Elaphe taeniura</i>. [PDF]

open access: yesZool Res
Zhang M   +12 more
europepmc   +1 more source

Sustainable two‐step functionalization of carbon fibers (CFs) with polyethyleneimine and investigation of curing kinetics in composite materials

open access: yesPolymer Composites, EarlyView.
We followed the functionalization steps outlined in the figure to obtain carbon fibers (CFs) functionalized with branched polyethyleneimine (b‐PEI). The entire process was carried out under mild conditions, including plasma activation and low‐temperature heating, using an eco‐friendly solvent (water).
Edoardo Albertini   +7 more
wiley   +1 more source

Treatment strategy for systemic lupus erythematosus using belimumab as indicated by multi‐omics analysis

open access: yesRheumatology &Autoimmunity, Volume 5, Issue 2, Page 81-87, June 2025.
Recent multi‐omics studies have demonstrated that belimumab specifically targets naïve B cells and a subset of memory B cells. This observation is consistent with belimumab's established efficacy and safety profile. Abstract Belimumab is an antibody targeting the cytokine B‐cell activating factor (BAFF), which is crucial for B cell differentiation, and
Keishi Fujio   +5 more
wiley   +1 more source

A case of IgG-type heavy chain amyloidosis with membranous nephropathy-like changes with long-term survival. [PDF]

open access: yesCEN Case Rep
Kono K   +14 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy